oral selective DNA-PK kinase inhibitor

synergy with radiotherapy in model

from library screen

Journal of Medicinal Chemistry

Bayer AG, Berlin, Germany


The Bayer DNA-PK inhibitor, BAY-8400, is an orally active and selective DNA-PK kinase inhibitor that synergistically enhances the efficacy of radiotherapeutics in xenograft models. The program started with a campaign…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: